BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35448188)

  • 1. Pain Relief after Stereotactic Radiotherapy of Pancreatic Adenocarcinoma: An Updated Systematic Review.
    Buwenge M; Arcelli A; Cellini F; Deodato F; Macchia G; Cilla S; Galietta E; Strigari L; Malizia C; Cammelli S; Morganti AG
    Curr Oncol; 2022 Apr; 29(4):2616-2629. PubMed ID: 35448188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic radiotherapy of pancreatic cancer: a systematic review on pain relief.
    Buwenge M; Macchia G; Arcelli A; Frakulli R; Fuccio L; Guerri S; Grassi E; Cammelli S; Cellini F; Morganti AG
    J Pain Res; 2018; 11():2169-2178. PubMed ID: 30323651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of stereotactic body radiation in the enhancement of the quality of life in locally advanced pancreatic adenocarcinoma: a systematic review.
    Vornhülz M; Anton S; Eross B; Szakács Z; Hegyi P; Regel I; Belka C; Niyazi M; Mayerle J; Beyer G
    Radiat Oncol; 2022 Jun; 17(1):108. PubMed ID: 35715808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC).
    Pavic M; Niyazi M; Wilke L; Corradini S; Vornhülz M; Mansmann U; Al Tawil A; Fritsch R; Hörner-Rieber J; Debus J; Guckenberger M; Belka C; Mayerle J; Beyer G
    Radiat Oncol; 2022 Jan; 17(1):18. PubMed ID: 35078490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review of stereotactic body radiotherapy for nodal metastases.
    Deodato F; Macchia G; Buwenge M; Bonetti M; Cilla S; Zamagni A; Re A; Pezzulla D; Cellini F; Strigari L; Valentini V; Morganti AG
    Clin Exp Metastasis; 2021 Feb; 38(1):11-29. PubMed ID: 33452954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
    Zhu X; Cao Y; Liu W; Ju X; Zhao X; Jiang L; Ye Y; Jin G; Zhang H
    Lancet Oncol; 2021 Aug; 22(8):1093-1102. PubMed ID: 34237249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
    Herman JM; Chang DT; Goodman KA; Dholakia AS; Raman SP; Hacker-Prietz A; Iacobuzio-Donahue CA; Griffith ME; Pawlik TM; Pai JS; O'Reilly E; Fisher GA; Wild AT; Rosati LM; Zheng L; Wolfgang CL; Laheru DA; Columbo LA; Sugar EA; Koong AC
    Cancer; 2015 Apr; 121(7):1128-37. PubMed ID: 25538019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials.
    Petrelli F; Comito T; Ghidini A; Torri V; Scorsetti M; Barni S
    Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):313-322. PubMed ID: 28068239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic body radiotherapy in pancreatic adenocarcinoma.
    de la Pinta C
    Hepatobiliary Pancreat Dis Int; 2024 Feb; 23(1):14-19. PubMed ID: 36990839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective.
    Ryan JF; Groot VP; Rosati LM; Hacker-Prietz A; Narang AK; McNutt TR; Jackson JF; Le DT; Jaffee EM; Zheng L; Laheru DA; He J; Pawlik TM; Weiss MJ; Wolfgang CL; Herman JM
    Ann Surg Oncol; 2018 Jan; 25(1):280-289. PubMed ID: 29063299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
    Zhu X; Cao Y; Liu W; Ju X; Zhao X; Jiang L; Ye Y; Jin G; Zhang H
    Lancet Oncol; 2022 Mar; 23(3):e105-e115. PubMed ID: 35240087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma.
    Simoni N; Micera R; Paiella S; Guariglia S; Zivelonghi E; Malleo G; Rossi G; Addari L; Giuliani T; Pollini T; Cavedon C; Salvia R; Milella M; Bassi C; Mazzarotto R
    Clin Oncol (R Coll Radiol); 2021 Jan; 33(1):e31-e38. PubMed ID: 32682686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of the Human Pancreatic Ductal Adenocarcinoma Immune Microenvironment by Stereotactic Body Radiotherapy.
    Mills BN; Qiu H; Drage MG; Chen C; Mathew JS; Garrett-Larsen J; Ye J; Uccello TP; Murphy JD; Belt BA; Lord EM; Katz AW; Linehan DC; Gerber SA
    Clin Cancer Res; 2022 Jan; 28(1):150-162. PubMed ID: 34862242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
    Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
    BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer.
    Schellenberg D; Goodman KA; Lee F; Chang S; Kuo T; Ford JM; Fisher GA; Quon A; Desser TS; Norton J; Greco R; Yang GP; Koong AC
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):678-86. PubMed ID: 18395362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing local progression after stereotactic body radiation therapy for unresectable pancreatic adenocarcinoma: CT versus PET.
    Toesca DAS; Pollom EL; Poullos PD; Flynt L; Cui Y; Quon A; von Eyben R; Koong AC; Chang DT
    Pract Radiat Oncol; 2017; 7(2):120-125. PubMed ID: 28274396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiotherapy (SBRT) for patients with locally advanced pancreatic cancer: A single center experience.
    Jumeau R; Delouya G; Roberge D; Donath D; Béliveau-Nadeau D; Campeau MP
    Dig Liver Dis; 2018 Apr; 50(4):396-400. PubMed ID: 29326012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review.
    de Geus SWL; Eskander MF; Kasumova GG; Ng SC; Kent TS; Mancias JD; Callery MP; Mahadevan A; Tseng JF
    Cancer; 2017 Nov; 123(21):4158-4167. PubMed ID: 28708929
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.